Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

204876 Complement C1q, Human

Complement C1q, Human, CAS 80295-33-6, is a native C1q complement component composed of 18 polypeptide chains consisting of three nonidentical A, B, C subunits of 29, 26, and 19 kDa, respectively.

Complement C1q, Human MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
204876
Purchase on Sigma-Aldrich

Przegląd

Replacement Information

Products

Numer katalogowyOpakowanie Ilość/opak.
204876-1MG Ampulka plastikowa 1 mg
Description
OverviewNative, human C1q complement component. Glycoprotein composed of 18 polypeptide chains consisting of three nonidentical subunits, A, B, and C, of M.W. 29 kDa, 26 kDa, and 19 kDa, respectively. Present in normal human serum at 70 µg/ml. Found in circulating blood plasma complexed with two C1r and two C1s molecules to form the first component of complement (C1). Activation of complement via classical pathway is triggered by binding of C1q to immune complexes containing IgG or IgM or to a variety of other activating substances, including C-reactive protein, retroviruses, and mitochondria. Subsequent to C1q binding, C1r and C1s are converted to proteolytic enzymes that are responsible for continuation of activation via the classical pathway.
Catalogue Number204876
Brand Family Calbiochem®
References
ReferencesLoos, M., et al. 1980. J. Immunol. 124, 59.
Kolb, W.P., et al. 1979. J. Immunol. 122, 2103.
Product Information
CAS number80295-33-6
FormLiquid
FormulationIn 300 mM NaCl, 10 mM HEPES, 40% glycerol, pH 7.2.
Quality LevelMQ200
Applications
Biological Information
Biological activity≥150,000 C1qH50 units/mg and ≥70% C1q activity in normal human serum on a mg/mg basis
Purity≥90% by SDS-PAGE
SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
ContaminantsIgG, IgA, IgM, C3, C4, albumin, fibrinogen, α₂-macroglobulin: ≤trace amounts
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Standard Handling
Storage ≤ -70°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numer katalogowy GTIN
204876-1MG 04055977219685

Documentation

Complement C1q, Human MSDS

Title

Safety Data Sheet (SDS) 

Complement C1q, Human Certificates of Analysis

TitleLot Number
204876

References

Przegląd literatury
Loos, M., et al. 1980. J. Immunol. 124, 59.
Kolb, W.P., et al. 1979. J. Immunol. 122, 2103.

Citations

Tytuł
  • Baruah, P., et al. 2006. Journal of Leukocyte Biology in press,.
  • Yuste, J., et al. 2006. Journal of Immunology 176, 6112.
    		•
    Data Sheet

    Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

    Revision27-May-2008 RFH
    DescriptionNative, human C1q complement component. Glycoprotein composed of 18 polypeptide chains consisting of three nonidentical subunits A, B, and C, of M.W. 29,000, 26,000 and 19,000, respectively. Present in normal human serum at 70 µg/ml. Found in circulating blood plasma complexed with two C1r and two C1s molecules to form the first component of complement (C1). Activation of complement via classical pathway is triggered by binding of C1q to immune complexes containing IgG or IgM or to a variety of other activating substances, including C-reactive protein, retroviruses, and mitochondria. Subsequent to C1q binding, C1r and C1s are converted to proteolytic enzymes that are responsible for continuation of activation via the classical pathway.
    FormLiquid
    FormulationIn 300 mM NaCl, 10 mM HEPES, 40% glycerol, pH 7.2.
    Concentration Label Please refer to vial label for lot-specific concentration
    SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
    CAS number80295-33-6
    Purity≥90% by SDS-PAGE
    ContaminantsIgG, IgA, IgM, C3, C4, albumin, fibrinogen, α₂-macroglobulin: ≤trace amounts
    Biological activity≥150,000 C1qH50 units/mg and ≥70% C1q activity in normal human serum on a mg/mg basis
    Storage Avoid freeze/thaw
    ≤ -70°C
    Do Not Freeze Ok to freeze
    Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
    Toxicity Standard Handling
    ReferencesLoos, M., et al. 1980. J. Immunol. 124, 59.
    Kolb, W.P., et al. 1979. J. Immunol. 122, 2103.
    Citation
  • Baruah, P., et al. 2006. Journal of Leukocyte Biology in press,.
  • Yuste, J., et al. 2006. Journal of Immunology 176, 6112.
    		•